Buy the di_老虎社区_美港股上老虎

2021-11-05

Buy the dip

Bionano Genomics stock tanked more than 8% in premarket trading<blockquote>Bionano Genomics股价在盘前交易中下跌超过8%</blockquote>

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":846403346,"tweetId":"846403346","gmtCreate":1636101335958,"gmtModify":1636101901935,"author":{"id":3561676944889444,"idStr":"3561676944889444","authorId":3561676944889444,"authorIdStr":"3561676944889444","name":"HappyTrade","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":20,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body>Buy the dip&nbsp;</body></html>","htmlText":"<html><head></head><body>Buy the dip&nbsp;</body></html>","text":"Buy the dip","highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/846403346","repostId":1194946622,"repostType":4,"repost":{"id":"1194946622","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1636101187,"share":"https://www.laohu8.com/m/news/1194946622?lang=zh_CN&edition=full","pubTime":"2021-11-05 16:33","market":"us","language":"en","title":"Bionano Genomics stock tanked more than 8% in premarket trading<blockquote>Bionano Genomics股价在盘前交易中下跌超过8%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1194946622","media":"Tiger Newspress","summary":"Bionano Genomics stock tanked more than 8% in premarket trading after Bionano Genomics Q3 net loss $","content":"Bionano Genomics stock tanked more than 8% in premarket trading&nbsp;after&nbsp;Bionano Genomics Q3 net loss $20.753M, sales $4.66M beat $4.23M estimate.<blockquote>Bionano Genomics第三季度净亏损2075.3万美元，销售额466万美元，超出预期423万美元，Bionano Genomics股价在盘前交易中下跌超过8%。</blockquote> <img src=\"https://static.tigerbbs.com/459633281a2e1ef6cef18931e8ba2b92\" tg-width=\"848\" tg-height=\"619\" width=\"100%\" height=\"auto\"><blockquote></blockquote> Bionano Genomics, Inc.&nbsp;reported financial results and business achievements for the quarter ended&nbsp;September&nbsp;30, 2021&nbsp;and highlighted recent corporate updates.<blockquote>生物纳米基因组学公司。报告了截至2021年9月30日的季度财务业绩和业务成就，并重点介绍了最近的公司更新。</blockquote> – Acquisition of BioDiscovery transforms Bionano from the structural variation company into a data solutions provider with the potential to offer the most comprehensive variant analysis platform in genomics<blockquote>-收购BioDiscovery将Bionano从结构变异公司转变为数据解决方案提供商，有潜力提供基因组学领域最全面的变异分析平台</blockquote> –&nbsp;Total revenue of$4.7 million, a 112% year-over-year total revenue increase, driven by growth in the Saphyr® installed base<blockquote>-在Saphyr增长的推动下，总收入为470万美元，总收入同比增长112%®已安装底座</blockquote> –&nbsp;Record number of Saphyr shipments and installations for any quarter to date<blockquote>-迄今为止任何季度Saphyr发货和安装数量均创历史新高</blockquote> –&nbsp;Launched protocols for ultra-high molecular weight DNA isolation from amniocentesis and chorionic villus sampling (CVS) for prenatal applications<blockquote>-推出用于产前应用的羊膜穿刺术和绒毛取样(CVS)中超高分子量DNA分离方案</blockquote> –&nbsp;Remaining 2021 milestones on track<blockquote>-2021年剩余里程碑步入正轨</blockquote> –&nbsp;Strong balance sheet with$326.1 millionin cash and short term investments as ofSeptember&nbsp;30, 2021<blockquote>-截至2021年9月30日，资产负债表强劲，现金和短期投资为3.261亿美元</blockquote> “We had the strongest quarter in Bionano’s history with a record number of Saphyr shipments and installations, including adoptions at several notable sites, including leading hospitals, cytogenetics labs and academic medical centers around the world. With the acquisition of BioDiscovery, a leading software company with best-in-class solutions for analysis, visualization, interpretation and reporting of genomics data. for microarray and next-generation sequencing (NGS), we are transitioningBionano Genomicsfrom being the structural variation company into a data solutions provider. We believe this will enable access to an expanded market opportunity by leveraging the NGS market through software. We are extremely pleased with the progress we are making and the fact that outstanding leaders are joining Bionano to join us in transforming the way the world sees the genome,” commentedErik Holmlin, PhD, Chief Executive Officer ofBionano Genomics.<blockquote>“我们经历了Bionano历史上最强劲的季度，Saphyr的出货量和安装量创历史新高，包括在几个著名地点的采用，包括世界各地的领先医院、细胞遗传学实验室和学术医疗中心。随着收购BioDiscovery，这是一家领先的软件公司，为基因组学数据的分析、可视化、解释和报告提供一流的解决方案。对于微阵列和下一代测序(NGS)，我们正在将Bionano Genomics从结构变异公司转变为数据解决方案提供商。我们相信，这将通过软件利用NGS市场来扩大市场机会。我们对我们所取得的进展以及杰出的领导者加入Bionano与我们一起改变世界看待基因组的方式感到非常高兴。”Bionano Genomics首席执行官Derik Holmlin博士评论道。</blockquote> Chris Stewart, Chief Financial Officer of Bionano added: “Q3 was another excellent quarter. We continued to achieve meaningful year-over-year revenue growth and maintained a strong balance sheet with$326 millionof cash and marketable securities as of the quarter-end. We also remain on track to achieve the milestones we laid out in the first quarter of 2021.”<blockquote>Bionano首席财务官克里斯·斯图尔特补充说：“第三季度是另一个出色的季度。我们继续实现收入同比有意义的增长，截至本季度末，我们保持着3.26亿美元现金和有价证券的强劲资产负债表。我们还继续实现我们在2021年第一季度制定的里程碑。”</blockquote> Key Business Highlights in Q3<blockquote>第三季度主要业务亮点</blockquote> The Company executed on its commercialization strategy, built scientific momentum by presenting data at key scientific meetings and drove utilization of Saphyr at key institutions across the globe, with the following highlights:<blockquote>该公司执行其商业化战略，通过在关键科学会议上展示数据来建立科学势头，并推动全球关键机构对Saphyr的利用，重点如下：</blockquote> –&nbsp;Expanded the installed base of Saphyr systems from 121 at the end of Q2 to 141 at the end of Q3. During the quarter endedSeptember 30,2021, we shipped a total of 24 Saphyr systems to the field, compared to 11 systems shipped in the same quarter in 2020.<blockquote>–将Saphyr系统的安装数量从第二季度末的121个扩大到第三季度末的141个截至2021年9月30日的季度，我们总共向现场运送了24套Saphyr系统，而2020年同季度运送了11套系统。</blockquote> –&nbsp;Sold 3,969 nanochannel array flow cells during the quarter endedSeptember 30, 2021,which is the most flow cells sold in any quarter ever and represents 122% growth over the same quarter in 2020.<blockquote>–截至2021年9月30日的季度售出3,969个纳米通道阵列流通池，这是有史以来任何季度销售最多的流动池，比2020年同季度增长了122%。</blockquote> –&nbsp;Commercial release of solutions for isolation of ultra-high molecular weight DNA for prenatal applicationssupporting the use of samples derived from amniocentesis and CVS. Bionano Prep SP Amnio and CVS Culture DNA Isolation Protocol supports both fresh cultures and cryopreserved cells, which expands the markets served for OGM.<blockquote>–用于产前应用的超高分子量DNA分离溶液的商业化发布支持使用来自羊膜穿刺术和CVS的样本。Bionano Prep SP羊膜和CVS培养DNA分离方案支持新鲜培养物和冷冻保存细胞，这扩大了OGM的市场。</blockquote> –&nbsp;OGM with Saphyr was adopted at several notable cytogenetics laboratories and academic medical centersinthe United States, including Brigham &amp; Woman’s Hospital, which is using OGM to identify structural variations in constitutional and cancer applications. Outside the US, Saphyr was adopted inAustralia,EuropeandChina.<blockquote>– 几个著名的细胞遗传学实验室和学术医学中心采用了带有Saphyr的OGM在美国，包括布莱根妇女医院，该医院正在使用OGM来识别体质和癌症应用中的结构变异。在美国以外，Saphyr被澳大利亚、欧洲和中国采用。</blockquote> –&nbsp;The largest clinical research study to date evaluating OGM was published inThe Journal of Molecular Diagnosticsfor a rare muscle disease, facioscapulohumeral muscular dystrophy, or FSHD, in about 351 patients. The results demonstrated that OGM provided data more quickly, accurately, and reproducibly than the current gold standard method of Southern blot analysis. The findings support the rationale for adopting OGM as an alternative to Southern blot analysis as OGM had a greater sizing accuracy as well as a greater than 99% concordance with Southern blot analysis.<blockquote>–迄今为止评估OGM的最大临床研究发表于分子诊断学杂志一种罕见的肌肉疾病，面肩肱肌营养不良症，或FSHD，在大约351名患者中。结果表明，与目前的Southern印迹分析的金标准方法相比，OGM提供的数据更快、更准确、更可重复。这些发现支持采用OGM作为Southern印迹分析的替代方案的基本原理，因为OGM具有更高的尺寸准确性以及与Southern印迹分析大于99%的一致性。</blockquote> –&nbsp;NuProbe Global, a global molecular diagnostics leader, adopted Saphyr to be integrated their proprietary tools,Quantitative Amplicon Sequencing (QASeq) and Blocker Displacement Amplification (BDA), for research and development efforts in reproductive health and oncology liquid biopsies.<blockquote>–全球分子诊断领导者NuProbe Global采用Saphyr集成其专有工具，定量扩增子测序（QASeq）和阻断剂置换扩增（BDA），用于生殖健康和肿瘤液体活检的研发工作。</blockquote> –&nbsp;Saphyr customers and Bionano conducted 10 presentations at the Annual Cancer Genomics Consortium Meeting inmid-August 2021,highlighting the benefits of OGM for clinical research applications in solid tumor analysis, hematological malignancies, products of conception, prenatal and postnatal constitutional genetics. More than 500 participants from around the globe attended virtually, highlighting the strong interest in OGM for cancer genomics.<blockquote>–Saphyr客户和Bionano在2021年8月中旬的年度癌症基因组学联盟会议上进行了10场演讲，强调OGM在实体瘤分析、血液恶性肿瘤、受孕产物、产前和产后体质遗传学等临床研究应用中的益处。来自全球各地的500多名参与者以虚拟方式参加了会议，凸显了OGM对癌症基因组学的浓厚兴趣。</blockquote> –&nbsp;Bionano customers presented 11 presentations on OGM at theEuropean Society of Human Genetics(ESHG) meeting in lateAugust 2021, demonstrating the clinical utility of OGM across many therapeutic application areas, along with the unique capabilities of Bionano’s Saphyr®system to detect all classes of structural variants, across the genome, at a superior resolution relative to traditional techniques.<blockquote>– Bionano客户在2021年8月下旬的欧洲人类遗传学会(ESHG)会议上发表了11篇有关OGM的演讲，展示了OGM在许多治疗应用领域的临床实用性，以及Bionano的Saphyr的独特能力®以相对于传统技术更高的分辨率检测整个基因组中所有类别的结构变异的系统。</blockquote> –&nbsp;Added exceptional talent across commercial leadership functions,includingAmanda Lettmannas Vice President of Global Customer Experience,Alex Helmas Vice President Strategic Product Marketing,Stephanie Hoyleas Vice President Corporate Marketing,Amanda Hernandezas Vice President of Global Sales Training and Development,Justin Leightonas Vice President and General Manager,Lineagen, andBob Hertsenbergas North America Sales Director.<blockquote>– 增加了跨商业领导职能的杰出人才，包括全球客户体验副总裁Amanda Lettmannas、战略产品营销副总裁Alex Helmas、企业营销副总裁Stephanie Hoyleas、全球销售培训和发展副总裁Amanda Hernandezas、Lineagen副总裁兼总经理Justin Leightonas和Bob Hertsenbergas北美销售总监。</blockquote> Financial Highlights<blockquote>财务摘要</blockquote> –&nbsp;Total revenue for the third quarter of 2021 was$4.7 million,up 21% from$3.9 millionin the second quarter and up 112% from$2.2 millionin the same period of 2020. The sequential increase was driven by increased demand for our Saphyr optical genome mapping solutions, including increased instrument sales and greater demand for our reagent rental program and consumables. The year-over-year increase was driven by both higher product sales and by the addition of revenue fromLineagen.<blockquote>–2021年第三季度总收入为470万美元，比第二季度的390万美元增长21%，比2020年同期的220万美元增长112%。环比增长是由对我们的Saphyr光学基因组图谱解决方案的需求增加推动的，包括仪器销售的增加以及对我们的试剂租赁计划和消耗品的更大需求。同比增长是由产品销量增加和Lineagen收入增加推动的。</blockquote> –&nbsp;Gross margin for the third quarter of 2021 was 24.8%,compared to 37.3% in the prior quarter and 33.4% from the third quarter of 2020. The decrease was primarily due to an increase in laboratory and warranty related expense that are expected to be non-recurring.<blockquote>–2021年第三季度毛利率为24.8%，相比之下，上一季度为37.3%，2020年第三季度为33.4%。这一下降主要是由于实验室和保修相关费用的增加，预计这些费用将是非经常性的。</blockquote> –&nbsp;Third quarter operating expense was$21.8 million,compared to$17.9&nbsp;million in the prior quarter and$11.0 millionin the third quarter of 2020. The sequential increase was mainly due to a$1.8 millionincrease in headcount and related expenses and a$1.5 millionincrease in Research and Development expenses related to expanding our supply chain to produce higher volumes. Third quarter operating expense included$2.8 millionof non-cash stock-based compensation. The year-over-year increase was primarily due to increased headcount-related spending as we build out all facets of our organization to support our expected commercial progress and increased research and development costs.<blockquote>–第三季度运营费用为2180万美元，相比之下，上一季度为1790万美元，2020年第三季度为1100万美元。环比增长主要是由于员工人数和相关费用增加了180万美元，以及与扩大供应链以提高产量相关的研发费用增加了150万美元。第三季度运营费用包括280万美元的非现金股票薪酬。同比增长主要是由于我们构建组织的各个方面以支持我们预期的商业进展以及研发成本的增加，因此与员工相关的支出增加。</blockquote> –&nbsp;AtSeptember&nbsp;30, 2021, the Company had cash, cash equivalents, and short-term investments of$326.1 millioncompared to cash and cash equivalents of$38.4 millionatDecember 31, 2020. The increase in cash is primarily due to the equity raises that were completed in the first quarter of 2021.<blockquote>– 截至2021年9月30日，公司拥有现金、现金等价物和短期投资3.261亿美元相比之下，2020年12月31日的现金和现金等价物为3840万美元。现金增加主要是由于2021年第一季度完成的股权融资。</blockquote> Remaining Anticipated Milestones for 2021 – Initiatives to Drive Global Adoption of Saphyr<blockquote>2021年剩余预期里程碑-推动全球采用Saphyr的举措</blockquote> –&nbsp;4Q21: Interim publication of results from pediatric clinical study<blockquote>-4 Q21：儿科临床研究结果的中期公布</blockquote> –&nbsp;4Q21: Validation of LDTs by 3 sites in both our prenatal clinical study and our pediatric clinical study<blockquote>-4 Q 21：在我们的产前临床研究和儿科临床研究中，3个研究中心对LDT的验证</blockquote> –&nbsp;4Q21: Initial prototype of next gen high throughput Saphyr<blockquote>-4Q21：下一代高通量Saphyr的初始原型</blockquote> –&nbsp;4Q21: Reach installed base of 150 systems to achieve a 50% increase over year end 2020<blockquote>-21年第四季度：达到150套系统的安装基础，较2020年底增长50%</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bionano Genomics stock tanked more than 8% in premarket trading<blockquote>Bionano Genomics股价在盘前交易中下跌超过8%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBionano Genomics stock tanked more than 8% in premarket trading<blockquote>Bionano Genomics股价在盘前交易中下跌超过8%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\nTiger Newspress \n2021-11-05 16:33\n</div>\n</a>\n</h4>\n</header>\n<article>\nBionano Genomics stock tanked more than 8% in premarket trading&nbsp;after&nbsp;Bionano Genomics Q3 net loss $20.753M, sales $4.66M beat $4.23M estimate.<blockquote>Bionano Genomics第三季度净亏损2075.3万美元，销售额466万美元，超出预期423万美元，Bionano Genomics股价在盘前交易中下跌超过8%。</blockquote> <img src=\"https://static.tigerbbs.com/459633281a2e1ef6cef18931e8ba2b92\" tg-width=\"848\" tg-height=\"619\" width=\"100%\" height=\"auto\"><blockquote></blockquote> Bionano Genomics, Inc.&nbsp;reported financial results and business achievements for the quarter ended&nbsp;September&nbsp;30, 2021&nbsp;and highlighted recent corporate updates.<blockquote>生物纳米基因组学公司。报告了截至2021年9月30日的季度财务业绩和业务成就，并重点介绍了最近的公司更新。</blockquote> – Acquisition of BioDiscovery transforms Bionano from the structural variation company into a data solutions provider with the potential to offer the most comprehensive variant analysis platform in genomics<blockquote>-收购BioDiscovery将Bionano从结构变异公司转变为数据解决方案提供商，有潜力提供基因组学领域最全面的变异分析平台</blockquote> –&nbsp;Total revenue of$4.7 million, a 112% year-over-year total revenue increase, driven by growth in the Saphyr® installed base<blockquote>-在Saphyr增长的推动下，总收入为470万美元，总收入同比增长112%®已安装底座</blockquote> –&nbsp;Record number of Saphyr shipments and installations for any quarter to date<blockquote>-迄今为止任何季度Saphyr发货和安装数量均创历史新高</blockquote> –&nbsp;Launched protocols for ultra-high molecular weight DNA isolation from amniocentesis and chorionic villus sampling (CVS) for prenatal applications<blockquote>-推出用于产前应用的羊膜穿刺术和绒毛取样(CVS)中超高分子量DNA分离方案</blockquote> –&nbsp;Remaining 2021 milestones on track<blockquote>-2021年剩余里程碑步入正轨</blockquote> –&nbsp;Strong balance sheet with$326.1 millionin cash and short term investments as ofSeptember&nbsp;30, 2021<blockquote>-截至2021年9月30日，资产负债表强劲，现金和短期投资为3.261亿美元</blockquote> “We had the strongest quarter in Bionano’s history with a record number of Saphyr shipments and installations, including adoptions at several notable sites, including leading hospitals, cytogenetics labs and academic medical centers around the world. With the acquisition of BioDiscovery, a leading software company with best-in-class solutions for analysis, visualization, interpretation and reporting of genomics data. for microarray and next-generation sequencing (NGS), we are transitioningBionano Genomicsfrom being the structural variation company into a data solutions provider. We believe this will enable access to an expanded market opportunity by leveraging the NGS market through software. We are extremely pleased with the progress we are making and the fact that outstanding leaders are joining Bionano to join us in transforming the way the world sees the genome,” commentedErik Holmlin, PhD, Chief Executive Officer ofBionano Genomics.<blockquote>“我们经历了Bionano历史上最强劲的季度，Saphyr的出货量和安装量创历史新高，包括在几个著名地点的采用，包括世界各地的领先医院、细胞遗传学实验室和学术医疗中心。随着收购BioDiscovery，这是一家领先的软件公司，为基因组学数据的分析、可视化、解释和报告提供一流的解决方案。对于微阵列和下一代测序(NGS)，我们正在将Bionano Genomics从结构变异公司转变为数据解决方案提供商。我们相信，这将通过软件利用NGS市场来扩大市场机会。我们对我们所取得的进展以及杰出的领导者加入Bionano与我们一起改变世界看待基因组的方式感到非常高兴。”Bionano Genomics首席执行官Derik Holmlin博士评论道。</blockquote> Chris Stewart, Chief Financial Officer of Bionano added: “Q3 was another excellent quarter. We continued to achieve meaningful year-over-year revenue growth and maintained a strong balance sheet with$326 millionof cash and marketable securities as of the quarter-end. We also remain on track to achieve the milestones we laid out in the first quarter of 2021.”<blockquote>Bionano首席财务官克里斯·斯图尔特补充说：“第三季度是另一个出色的季度。我们继续实现收入同比有意义的增长，截至本季度末，我们保持着3.26亿美元现金和有价证券的强劲资产负债表。我们还继续实现我们在2021年第一季度制定的里程碑。”</blockquote> Key Business Highlights in Q3<blockquote>第三季度主要业务亮点</blockquote> The Company executed on its commercialization strategy, built scientific momentum by presenting data at key scientific meetings and drove utilization of Saphyr at key institutions across the globe, with the following highlights:<blockquote>该公司执行其商业化战略，通过在关键科学会议上展示数据来建立科学势头，并推动全球关键机构对Saphyr的利用，重点如下：</blockquote> –&nbsp;Expanded the installed base of Saphyr systems from 121 at the end of Q2 to 141 at the end of Q3. During the quarter endedSeptember 30,2021, we shipped a total of 24 Saphyr systems to the field, compared to 11 systems shipped in the same quarter in 2020.<blockquote>–将Saphyr系统的安装数量从第二季度末的121个扩大到第三季度末的141个截至2021年9月30日的季度，我们总共向现场运送了24套Saphyr系统，而2020年同季度运送了11套系统。</blockquote> –&nbsp;Sold 3,969 nanochannel array flow cells during the quarter endedSeptember 30, 2021,which is the most flow cells sold in any quarter ever and represents 122% growth over the same quarter in 2020.<blockquote>–截至2021年9月30日的季度售出3,969个纳米通道阵列流通池，这是有史以来任何季度销售最多的流动池，比2020年同季度增长了122%。</blockquote> –&nbsp;Commercial release of solutions for isolation of ultra-high molecular weight DNA for prenatal applicationssupporting the use of samples derived from amniocentesis and CVS. Bionano Prep SP Amnio and CVS Culture DNA Isolation Protocol supports both fresh cultures and cryopreserved cells, which expands the markets served for OGM.<blockquote>–用于产前应用的超高分子量DNA分离溶液的商业化发布支持使用来自羊膜穿刺术和CVS的样本。Bionano Prep SP羊膜和CVS培养DNA分离方案支持新鲜培养物和冷冻保存细胞，这扩大了OGM的市场。</blockquote> –&nbsp;OGM with Saphyr was adopted at several notable cytogenetics laboratories and academic medical centersinthe United States, including Brigham &amp; Woman’s Hospital, which is using OGM to identify structural variations in constitutional and cancer applications. Outside the US, Saphyr was adopted inAustralia,EuropeandChina.<blockquote>– 几个著名的细胞遗传学实验室和学术医学中心采用了带有Saphyr的OGM在美国，包括布莱根妇女医院，该医院正在使用OGM来识别体质和癌症应用中的结构变异。在美国以外，Saphyr被澳大利亚、欧洲和中国采用。</blockquote> –&nbsp;The largest clinical research study to date evaluating OGM was published inThe Journal of Molecular Diagnosticsfor a rare muscle disease, facioscapulohumeral muscular dystrophy, or FSHD, in about 351 patients. The results demonstrated that OGM provided data more quickly, accurately, and reproducibly than the current gold standard method of Southern blot analysis. The findings support the rationale for adopting OGM as an alternative to Southern blot analysis as OGM had a greater sizing accuracy as well as a greater than 99% concordance with Southern blot analysis.<blockquote>–迄今为止评估OGM的最大临床研究发表于分子诊断学杂志一种罕见的肌肉疾病，面肩肱肌营养不良症，或FSHD，在大约351名患者中。结果表明，与目前的Southern印迹分析的金标准方法相比，OGM提供的数据更快、更准确、更可重复。这些发现支持采用OGM作为Southern印迹分析的替代方案的基本原理，因为OGM具有更高的尺寸准确性以及与Southern印迹分析大于99%的一致性。</blockquote> –&nbsp;NuProbe Global, a global molecular diagnostics leader, adopted Saphyr to be integrated their proprietary tools,Quantitative Amplicon Sequencing (QASeq) and Blocker Displacement Amplification (BDA), for research and development efforts in reproductive health and oncology liquid biopsies.<blockquote>–全球分子诊断领导者NuProbe Global采用Saphyr集成其专有工具，定量扩增子测序（QASeq）和阻断剂置换扩增（BDA），用于生殖健康和肿瘤液体活检的研发工作。</blockquote> –&nbsp;Saphyr customers and Bionano conducted 10 presentations at the Annual Cancer Genomics Consortium Meeting inmid-August 2021,highlighting the benefits of OGM for clinical research applications in solid tumor analysis, hematological malignancies, products of conception, prenatal and postnatal constitutional genetics. More than 500 participants from around the globe attended virtually, highlighting the strong interest in OGM for cancer genomics.<blockquote>–Saphyr客户和Bionano在2021年8月中旬的年度癌症基因组学联盟会议上进行了10场演讲，强调OGM在实体瘤分析、血液恶性肿瘤、受孕产物、产前和产后体质遗传学等临床研究应用中的益处。来自全球各地的500多名参与者以虚拟方式参加了会议，凸显了OGM对癌症基因组学的浓厚兴趣。</blockquote> –&nbsp;Bionano customers presented 11 presentations on OGM at theEuropean Society of Human Genetics(ESHG) meeting in lateAugust 2021, demonstrating the clinical utility of OGM across many therapeutic application areas, along with the unique capabilities of Bionano’s Saphyr®system to detect all classes of structural variants, across the genome, at a superior resolution relative to traditional techniques.<blockquote>– Bionano客户在2021年8月下旬的欧洲人类遗传学会(ESHG)会议上发表了11篇有关OGM的演讲，展示了OGM在许多治疗应用领域的临床实用性，以及Bionano的Saphyr的独特能力®以相对于传统技术更高的分辨率检测整个基因组中所有类别的结构变异的系统。</blockquote> –&nbsp;Added exceptional talent across commercial leadership functions,includingAmanda Lettmannas Vice President of Global Customer Experience,Alex Helmas Vice President Strategic Product Marketing,Stephanie Hoyleas Vice President Corporate Marketing,Amanda Hernandezas Vice President of Global Sales Training and Development,Justin Leightonas Vice President and General Manager,Lineagen, andBob Hertsenbergas North America Sales Director.<blockquote>– 增加了跨商业领导职能的杰出人才，包括全球客户体验副总裁Amanda Lettmannas、战略产品营销副总裁Alex Helmas、企业营销副总裁Stephanie Hoyleas、全球销售培训和发展副总裁Amanda Hernandezas、Lineagen副总裁兼总经理Justin Leightonas和Bob Hertsenbergas北美销售总监。</blockquote> Financial Highlights<blockquote>财务摘要</blockquote> –&nbsp;Total revenue for the third quarter of 2021 was$4.7 million,up 21% from$3.9 millionin the second quarter and up 112% from$2.2 millionin the same period of 2020. The sequential increase was driven by increased demand for our Saphyr optical genome mapping solutions, including increased instrument sales and greater demand for our reagent rental program and consumables. The year-over-year increase was driven by both higher product sales and by the addition of revenue fromLineagen.<blockquote>–2021年第三季度总收入为470万美元，比第二季度的390万美元增长21%，比2020年同期的220万美元增长112%。环比增长是由对我们的Saphyr光学基因组图谱解决方案的需求增加推动的，包括仪器销售的增加以及对我们的试剂租赁计划和消耗品的更大需求。同比增长是由产品销量增加和Lineagen收入增加推动的。</blockquote> –&nbsp;Gross margin for the third quarter of 2021 was 24.8%,compared to 37.3% in the prior quarter and 33.4% from the third quarter of 2020. The decrease was primarily due to an increase in laboratory and warranty related expense that are expected to be non-recurring.<blockquote>–2021年第三季度毛利率为24.8%，相比之下，上一季度为37.3%，2020年第三季度为33.4%。这一下降主要是由于实验室和保修相关费用的增加，预计这些费用将是非经常性的。</blockquote> –&nbsp;Third quarter operating expense was$21.8 million,compared to$17.9&nbsp;million in the prior quarter and$11.0 millionin the third quarter of 2020. The sequential increase was mainly due to a$1.8 millionincrease in headcount and related expenses and a$1.5 millionincrease in Research and Development expenses related to expanding our supply chain to produce higher volumes. Third quarter operating expense included$2.8 millionof non-cash stock-based compensation. The year-over-year increase was primarily due to increased headcount-related spending as we build out all facets of our organization to support our expected commercial progress and increased research and development costs.<blockquote>–第三季度运营费用为2180万美元，相比之下，上一季度为1790万美元，2020年第三季度为1100万美元。环比增长主要是由于员工人数和相关费用增加了180万美元，以及与扩大供应链以提高产量相关的研发费用增加了150万美元。第三季度运营费用包括280万美元的非现金股票薪酬。同比增长主要是由于我们构建组织的各个方面以支持我们预期的商业进展以及研发成本的增加，因此与员工相关的支出增加。</blockquote> –&nbsp;AtSeptember&nbsp;30, 2021, the Company had cash, cash equivalents, and short-term investments of$326.1 millioncompared to cash and cash equivalents of$38.4 millionatDecember 31, 2020. The increase in cash is primarily due to the equity raises that were completed in the first quarter of 2021.<blockquote>– 截至2021年9月30日，公司拥有现金、现金等价物和短期投资3.261亿美元相比之下，2020年12月31日的现金和现金等价物为3840万美元。现金增加主要是由于2021年第一季度完成的股权融资。</blockquote> Remaining Anticipated Milestones for 2021 – Initiatives to Drive Global Adoption of Saphyr<blockquote>2021年剩余预期里程碑-推动全球采用Saphyr的举措</blockquote> –&nbsp;4Q21: Interim publication of results from pediatric clinical study<blockquote>-4 Q21：儿科临床研究结果的中期公布</blockquote> –&nbsp;4Q21: Validation of LDTs by 3 sites in both our prenatal clinical study and our pediatric clinical study<blockquote>-4 Q 21：在我们的产前临床研究和儿科临床研究中，3个研究中心对LDT的验证</blockquote> –&nbsp;4Q21: Initial prototype of next gen high throughput Saphyr<blockquote>-4Q21：下一代高通量Saphyr的初始原型</blockquote> –&nbsp;4Q21: Reach installed base of 150 systems to achieve a 50% increase over year end 2020<blockquote>-21年第四季度：达到150套系统的安装基础，较2020年底增长50%</blockquote>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNGO":"Bionano Genomics"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1194946622","content_text":"Bionano Genomics stock tanked more than 8% in premarket trading after Bionano Genomics Q3 net loss $20.753M, sales $4.66M beat $4.23M estimate.\n\nBionano Genomics, Inc. reported financial results and business achievements for the quarter ended September 30, 2021 and highlighted recent corporate updates.\n– Acquisition of BioDiscovery transforms Bionano from the structural variation company into a data solutions provider with the potential to offer the most comprehensive variant analysis platform in genomics\n– Total revenue of$4.7 million, a 112% year-over-year total revenue increase, driven by growth in the Saphyr® installed base\n– Record number of Saphyr shipments and installations for any quarter to date\n– Launched protocols for ultra-high molecular weight DNA isolation from amniocentesis and chorionic villus sampling (CVS) for prenatal applications\n– Remaining 2021 milestones on track\n– Strong balance sheet with$326.1 millionin cash and short term investments as ofSeptember 30, 2021\n“We had the strongest quarter in Bionano’s history with a record number of Saphyr shipments and installations, including adoptions at several notable sites, including leading hospitals, cytogenetics labs and academic medical centers around the world. With the acquisition of BioDiscovery, a leading software company with best-in-class solutions for analysis, visualization, interpretation and reporting of genomics data. for microarray and next-generation sequencing (NGS), we are transitioningBionano Genomicsfrom being the structural variation company into a data solutions provider. We believe this will enable access to an expanded market opportunity by leveraging the NGS market through software. We are extremely pleased with the progress we are making and the fact that outstanding leaders are joining Bionano to join us in transforming the way the world sees the genome,” commentedErik Holmlin, PhD, Chief Executive Officer ofBionano Genomics.\nChris Stewart, Chief Financial Officer of Bionano added: “Q3 was another excellent quarter. We continued to achieve meaningful year-over-year revenue growth and maintained a strong balance sheet with$326 millionof cash and marketable securities as of the quarter-end. We also remain on track to achieve the milestones we laid out in the first quarter of 2021.”\nKey Business Highlights in Q3\nThe Company executed on its commercialization strategy, built scientific momentum by presenting data at key scientific meetings and drove utilization of Saphyr at key institutions across the globe, with the following highlights:\n– Expanded the installed base of Saphyr systems from 121 at the end of Q2 to 141 at the end of Q3. During the quarter endedSeptember 30,2021, we shipped a total of 24 Saphyr systems to the field, compared to 11 systems shipped in the same quarter in 2020.\n– Sold 3,969 nanochannel array flow cells during the quarter endedSeptember 30, 2021,which is the most flow cells sold in any quarter ever and represents 122% growth over the same quarter in 2020.\n– Commercial release of solutions for isolation of ultra-high molecular weight DNA for prenatal applicationssupporting the use of samples derived from amniocentesis and CVS. Bionano Prep SP Amnio and CVS Culture DNA Isolation Protocol supports both fresh cultures and cryopreserved cells, which expands the markets served for OGM.\n– OGM with Saphyr was adopted at several notable cytogenetics laboratories and academic medical centersinthe United States, including Brigham & Woman’s Hospital, which is using OGM to identify structural variations in constitutional and cancer applications. Outside the US, Saphyr was adopted inAustralia,EuropeandChina.\n– The largest clinical research study to date evaluating OGM was published inThe Journal of Molecular Diagnosticsfor a rare muscle disease, facioscapulohumeral muscular dystrophy, or FSHD, in about 351 patients. The results demonstrated that OGM provided data more quickly, accurately, and reproducibly than the current gold standard method of Southern blot analysis. The findings support the rationale for adopting OGM as an alternative to Southern blot analysis as OGM had a greater sizing accuracy as well as a greater than 99% concordance with Southern blot analysis.\n– NuProbe Global, a global molecular diagnostics leader, adopted Saphyr to be integrated their proprietary tools,Quantitative Amplicon Sequencing (QASeq) and Blocker Displacement Amplification (BDA), for research and development efforts in reproductive health and oncology liquid biopsies.\n– Saphyr customers and Bionano conducted 10 presentations at the Annual Cancer Genomics Consortium Meeting inmid-August 2021,highlighting the benefits of OGM for clinical research applications in solid tumor analysis, hematological malignancies, products of conception, prenatal and postnatal constitutional genetics. More than 500 participants from around the globe attended virtually, highlighting the strong interest in OGM for cancer genomics.\n– Bionano customers presented 11 presentations on OGM at theEuropean Society of Human Genetics(ESHG) meeting in lateAugust 2021, demonstrating the clinical utility of OGM across many therapeutic application areas, along with the unique capabilities of Bionano’s Saphyr®system to detect all classes of structural variants, across the genome, at a superior resolution relative to traditional techniques.\n– Added exceptional talent across commercial leadership functions,includingAmanda Lettmannas Vice President of Global Customer Experience,Alex Helmas Vice President Strategic Product Marketing,Stephanie Hoyleas Vice President Corporate Marketing,Amanda Hernandezas Vice President of Global Sales Training and Development,Justin Leightonas Vice President and General Manager,Lineagen, andBob Hertsenbergas North America Sales Director.\nFinancial Highlights\n– Total revenue for the third quarter of 2021 was$4.7 million,up 21% from$3.9 millionin the second quarter and up 112% from$2.2 millionin the same period of 2020. The sequential increase was driven by increased demand for our Saphyr optical genome mapping solutions, including increased instrument sales and greater demand for our reagent rental program and consumables. The year-over-year increase was driven by both higher product sales and by the addition of revenue fromLineagen.\n– Gross margin for the third quarter of 2021 was 24.8%,compared to 37.3% in the prior quarter and 33.4% from the third quarter of 2020. The decrease was primarily due to an increase in laboratory and warranty related expense that are expected to be non-recurring.\n– Third quarter operating expense was$21.8 million,compared to$17.9 million in the prior quarter and$11.0 millionin the third quarter of 2020. The sequential increase was mainly due to a$1.8 millionincrease in headcount and related expenses and a$1.5 millionincrease in Research and Development expenses related to expanding our supply chain to produce higher volumes. Third quarter operating expense included$2.8 millionof non-cash stock-based compensation. The year-over-year increase was primarily due to increased headcount-related spending as we build out all facets of our organization to support our expected commercial progress and increased research and development costs.\n– AtSeptember 30, 2021, the Company had cash, cash equivalents, and short-term investments of$326.1 millioncompared to cash and cash equivalents of$38.4 millionatDecember 31, 2020. The increase in cash is primarily due to the equity raises that were completed in the first quarter of 2021.\nRemaining Anticipated Milestones for 2021 – Initiatives to Drive Global Adoption of Saphyr\n– 4Q21: Interim publication of results from pediatric clinical study\n– 4Q21: Validation of LDTs by 3 sites in both our prenatal clinical study and our pediatric clinical study\n– 4Q21: Initial prototype of next gen high throughput Saphyr\n– 4Q21: Reach installed base of 150 systems to achieve a 50% increase over year end 2020","news_type":1,"symbols_score_info":{"BNGO":0.9}},"isVote":1,"tweetType":1,"viewCount":1206,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":9,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/846403346"}